Objective: Hispanics have lower rates of hypertension control compared with black and white patients. Nebivolol is a vasodilatory ß1-selective blocker, with neutral metabolic effects. This phase IV trial evaluated the efficacy and safety of nebivolol in Hispanics with stage III hypertension. Methods: Self-identified Hispanics with stage III hypertension were randomized to receive a double-blind treatment: placebo (n ¼ 136) or nebivolol (n ¼ 141, starting dose 5 mg/day) for 8 weeks. Nebivolol dosage could be uptitrated at 2-week intervals to 10, 20, or 40 mg/day, as needed to achieve diastolic blood pressure (DBP) control (JNC7 criteria). Efficacy outcome measures were the mean changes from baseline to the end of week 8 in trough-seated DBP (primary) and systolic blood pressure (SBP) (secondary). Safety and tolerability were also assessed. Results: Baseline SBP/DBP (mmHg) was similar in both treatment groups (nebivolol: 156/100; placebo: 157/101). A total of 135 (96%) and 121 (89%) nebivolol-and placebo-treated participants completed the double-blind phase, respectively. Compared with the placebo, nebivolol treatment was associated with significant mean reductions in both trough-seated DBP and SBP (DBP: À11.1 mmHg vs. À7.3 mmHg, p < 0.0001; SBP: À14.1 mmHg vs. À9.3 mmHg; p ¼ 0.001). Treatment-emergent adverse event (TEAE) rates were 17% (nebivolol) and 22% (placebo); the most frequent TEAEs were headache (4% vs. 6%, respectively), upper respiratory tract infection (2% vs. 2%), and dizziness (1% vs. 3%). Conclusions: In Hispanics with stage III hypertension, 8-week nebivolol monotherapy resulted in significant reductions in blood pressure. The safety and tolerability profile of nebivolol was similar to that of placebo.
Introduction
Hispanics, defined as individuals of Mexican, Puerto Rican, Cuban, Central American, South American, or Spanish descent, are the largest and fastest growing minority group in the USA, currently representing 15% of the total US population. Mexican Americans are the largest Hispanic ethnicity in the USA (64.0%), followed by individuals of Puerto Rican (9.0%) and Central American (7.6%) heritage. Data collected in the National Health and Nutrition Examination Surveys (NHANES) between 1999 and 2008 show that the prevalence of hypertension in Mexican Americans (or Hispanics, as defined in the 20072008 survey) has been on average similar to that observed in non-Hispanic whites, and lower than the prevalence observed in non-Hispanic blacks [Egan et al. 2010] . However, in the same period, the Mexican American/ Hispanic population was also characterized by the lowest rates of hypertension awareness and treatment among the three racial/ethnic groups, which was also accompanied by the lowest rates of hypertension control [Egan et al. 2010] . Hispanics, compared with non-Hispanic whites, are also more exposed to several risk factors for hypertension, including diabetes (prevalence of 12.5% among Mexican Americans vs. 6.4% among non-Hispanic whites) [Lloyd-Jones et al. 2010] , obesity (body mass index !30 kg/m 2 ; 71.6% among Hispanic women vs. 61.2% among non-Hispanic white women) [Flegal et al. 2010; Lloyd-Jones et al. 2010] , metabolic syndrome [Park and Taylor, 2007; Ford et al. 2002] , and a more limited access to regular healthcare [Stewart and Silverstein, 2002] . Few prospectively designed studies have evaluated the effects of antihypertensive medication in Hispanics or were sufficiently powered to allow for post hoc analysis of the Hispanic subpopulation [Park and Taylor, 2007] .
Nebivolol is a ß 1 -selective beta-blocker with nitric oxide (NO)-mediated vasodilatory properties [Munzel and Gori, 2009] , approved for the treatment of stage III hypertension [Greathouse, 2010; Saunders et al. 2007; Weiss et al. 2007] . Available preclinical data indicate that human umbilical vein endothelial cells (HUVECs) obtained from Mexican American donors exhibit significantly lower NO levels, compared with HUVECs from non-Hispanic whites, and that NO release in HUVECs from both Mexican Americans and non-Hispanic whites is significantly augmented following nebivolol treatment [Mason Rp, 2007] . Several clinical trials have shown that nebivolol effectively reduces blood pressure (BP) across a range of patients, including those with diabetes [Schmidt et al. 2007] or impaired glucose tolerance (IGT) [Poirier et al. 2001] , and those considered obese [Manrique et al. 2009 ]. Hispanics were underrepresented in pivotal nebivolol trials NEB-MD-302 (n ¼ 123; 13.5%) [Weiss et al. 2007] and NEB-MD-305 (n ¼ 59; 7.3%) [Greathouse, 2010] , and post hoc analyses of their data were inconclusive, due to a relatively small number of participants and a relatively large placebo effect (data on file).
The aim of this study was to evaluate the efficacy and safety of nebivolol monotherapy in Hispanics with stage III hypertension. This is the first prospectively designed, randomized, placebocontrolled clinical study designed to evaluate the effects of nebivolol in Hispanics.
Methods

Participants
The study was conducted in 29 centers in the USA and Puerto Rico from 3 November 2008 to 9 September 2009. It was approved at each institution by either its own review board or the Copernicus Central Institutional Review Board, and performed in accordance with the Declaration of Helsinki. Study participants were adult men and women, self-identified as being of Hispanic or Latino ethnicity (any race of Mexican, Puerto Rican, Dominican, Cuban, and Central or South American heritage), with a diagnosis of stage III hypertension (a mean sitting diastolic blood pressure [DBP] of 95110 mmHg). Untreated or newly diagnosed participants (trough-seated DBP 95114 mmHg) or participants treated with no more than two antihypertensive medications (trough-seated DBP 60114 mmHg) were included. Each individual provided a written informed consent to participate in the trial.
Participants could not enroll if they had secondary hypertension (e.g. renal artery stenosis, chronic renal disease, pheochromocytoma, primary aldosteronism), or severe hypertension (systolic blood pressure [SBP] !180 mmHg or DBP !115 mmHg), clinically significant respiratory disease that prohibited the use of a betablocker, or coronary artery disease that required treatment with a beta-blocker, calcium channel blocker, or chronic nitrates. Enrolled participants could not have had a history of clinically significant cardiovascular disease (CVD) (e.g. arrhythmia, coronary bypass grafting, or myocardial infarction) within 6 months of study entry. Those with heart failure, resting heart rate of <60 beats per minute (bpm) at screening, substance abuse, active liver disease or renal impairment, use of prohibited concomitant medications within 1 month of screening, uncontrolled type I or II diabetes mellitus, or thyroid disease were also excluded.
Study design
Following a 1-week screening phase, participants entered a 4-week, single-blind, placebo washout phase. Participants who completed the singleblind placebo phase with a mean trough-seated DBP of 95114 mmHg and SBP of <180 mmHg were randomized to receive placebo or nebivolol (starting dose, 5 mg/day) during an 8-week double-blind phase. Randomization was performed and conducted by means of an interactive voice response system. Participants were randomized at each study center, based on sequence of study entry. Randomization lists were generated and retained by the statistical programming department of the Forest Research Institute. During the double-blind treatment phase, the nebivolol dose could be uptitrated in a stepwise Therapeutic Advances in Cardiovascular Disease 4 (6) manner to achieve DBP control (DBP <80 mmHg or <90 mmHg, for participants with or without diabetes mellitus, respectively). If DBP control was not achieved with the starting dosage of 5 mg/day, it could be uptitrated to 10 mg/day at the end of week 2. Individuals receiving 10 mg/day who did not reach DBP control by the end of week 4 were uptitrated to 20 mg/day; those treated with 20 mg/day and did not reach DBP control by the end of week 6 were uptitrated to 40 mg/day. Participants were required to remain on the dosage that was initially needed to achieve DBP control, even if they could not maintain it through to the end of the double-blind period (end of week 8). The 8-week, double-blind, placebo-controlled treatment phase was followed by a 1-week, doubleblind, down-titration phase.
BP and heart rate measurements BP was measured at each study visit and was reported as the mean of three separate measurements, separated by 25-min intervals; measurements were performed by trained study site staff on the seated participant's nondominant arm, using an automated BP monitor (Model HEM-705CP, manufactured by Omron Healthcare, Inc; cuff size 913 inches [regular] or 1317 inches [large]) or a mercury sphygmomanometer. Participants were asked to abstain from caffeine, smoking, or strenuous exercise for 2 h before BP measurements, and from phosphodiesterase type 5 inhibitors and nonsteroidal anti-inflammatory agents for 48 h prior to BP measurements. All BP measurements in the same patient were performed using the same method for the duration of the study. Heart rate (HR) was measured at each study visit for 60 s (average of three measurements). With the exception of the first (screening) visit, all vital signs were measured at trough (24±2 h after the most recent dose).
Outcome measures
The primary and secondary efficacy endpoints were mean baseline-to-endpoint changes in trough-seated DBP and SBP, respectively. Additional outcomes included mean changes from baseline to each postbaseline visit in trough-seated DBP, SBP, and resting HR. Safety and tolerability were assessed at each study visit by means of physical examination, clinical laboratory parameters, vital signs, and recording of adverse events (AEs); electrocardiogram (ECG) analysis was performed at screening and study endpoint (week 8).
Data analysis
Statistical analyses were based on the intent-totreat population, with the last observation carried forward approach for imputation of missing values. Mean changes in trough-seated DBP, SBP, and HR were analyzed using an analysis of covariance model, with treatment group, study center, and baseline obesity status as factors, and baseline value as a covariate. All statistical tests were two-sided, performed at the 5% significance level (a ¼ 0.05) for main effects. All confidence intervals were two-sided 95% confidence intervals.
Results
Baseline characteristics and patient disposition
Out of the 949 participants who entered the placebo washout phase, 277 (29.2%) met the BP criteria to be randomized into the double-blind treatment phase. The treatment groups were similar in terms of their baseline demographic and clinical characteristics; the majority of participants were men (59.2%), obese (60.3%), and classified with stage II hypertension (60.6%), and a total of 18 (6.5%) individuals had a history of CV events or CVDs (Table 1) . A total of 260 (93.9%) participants were self-identified as white; the most commonly reported ethnicity was Cuban (37.9%), followed by Mexican (27.1%), and Central/South American (22.0%) ( Table 1) .
A total of 121 (89.0%) placebo-treated and 135 (95.7%) nebivolol-treated participants completed the double-blind treatment phase; six (4.4%) placebo-treated participants discontinued the double-blind treatment phase due to an AE (Figure 1) . By the end of week 8, 31 (22.0%) participants remained at the initial dosage of 5 mg/day, 21 (14.9%) were uptitrated to 10 mg/ day, 20 (14.2%) to 20 mg/day, and 69 (48.9%) to 40 mg/day. Treatment adherence was greater than 99% for all study medications.
Effects of nebivolol on BP and HR
At the end of week 8, nebivolol (all dosage subgroups pooled) was significantly more effective than placebo in reducing trough-seated DBP (À11.1 mmHg vs. À7.3 mmHg; p < 0.0001) and trough-seated SBP (À14.1 mmHg vs. À9.3 mmHg; p ¼ 0.001) (Figure 2 , Table 2 ). A significant difference in DBP and SBP changes between nebivolol-and placebo-treated participants was achieved at the first postbaseline visit (week 2), when all nebivolol-treated participants were receiving the initial dosage of 5 mg/day; the effect was maintained throughout the doubleblind treatment phase (Figure 3) . The proportions of nebivolol-treated participants who reached DBP control at study endpoint (i.e. DBP <80 mmHg or <90 mmHg for individuals without or with diabetes, respectively) were 71% (treated with 5 mg/day), 62% (10 mg/day), 75% (20 mg/day), and 32% (40 mg/day). Nebivolol also significantly reduced trough-seated HR (mean±standard deviation) over placebo at week 8 (endpoint: À7.5±10.2 bpm vs. À2.4±10.5 bpm, p < 0.0001), (Table 2) , with a significant effect also observed at all interim study visits (p < 0.01 for all dosages vs. placebo).
In a post hoc subgroup analysis, nebivolol effectively reduced trough-seated DBP over placebo in obese (À10.2 mmHg vs. À7.5 mmHg, p ¼ 0.012; n ¼ 166) and nonobese (À12.3 mmHg vs. À6.9 mmHg, p ¼ 0.004; n ¼ 110) participants; SBP was also reduced in obese (À13.6 mmHg vs. À10.4 mmHg, p ¼ 0.067), and nonobese (À14.7 mmHg vs. À7.8 mmHg, p ¼ 0.018) participants.
Safety and tolerability
During the double-blind treatment phase, treatment-emergent AEs (TEAEs) were reported in 30 (22.1%) placebo-treated and 24 (17.0%) nebivolol-treated participants. TEAEs reported by at least 2% of placebo-or nebivolol-treated participants are presented in Numbers of placebo-and nebivolol-treated participants who experienced potentially clinically significant changes in ECG and blood or urine analyses were similar (data not shown). During the double-blind treatment phase, a greater proportion of nebivolol-treated participants experienced a change from normal to low levels of hemoglobin (5.5% vs. 1.7%) and a change from normal to high levels of ALT (6.6% vs. 4.8%), Figure 2 . Effects of nebivolol treatment on blood pressure in Hispanics with stage III hypertension, mean change from baseline to week 8 (LOCF; ITT population). ***p < 0.001; nebivolol versus placebo. DBP, diastolic blood pressure; ITT, intent-to-treat; LOCF, last observation carried forward; SBP, systolic blood pressure, SEM, standard error of the mean.
whereas more placebo-treated individuals experienced a change from normal to high levels of fasting glucose (10.0% vs. 12.5%). The overall incidence of potentially clinically significant changes in hemoglobin-, ALT-, and fasting glucose-levels was low and similar between the treatment groups.
Discussion
The study demonstrated that nebivolol monotherapy effectively reduces blood pressure in Hispanics with stage III hypertension, with a significant effect observable beginning at week 2, when all patients received the lowest dosage of 5 mg/day. Treatment with nebivolol was safe and well tolerated, with a low overall incidence of AEs, comparable with AE incidence observed in the placebo group. Furthermore, no nebivolol-treated patient discontinued the trial due to an AE.
The results of this study support findings from other nebivolol trials in hypertension [Greathouse, 2010; Neutel et al. 2009; Saunders et al. 2007; Weiss et al. 2007; Van Nueten et al. 1998 , 1997 : nebivolol is efficacious in reducing BP in participants with stage III hypertension, associated with an AE rate similar to that of placebo, and a low rate of AEs commonly associated with beta-blocker use (dyspnea, 0%; fatigue, 0%; sexual dysfunction, 0.7%) [Munzel and Gori, 2009 ]. The relatively low incidence of AEs in this study and other nebivolol clinical trials [Ambrosioni and Borghi, 2005] may be attributable to its high ß1-selectivity and NO-mediated vasodilatory effects [Munzel and Gori, 2009] .
To the best of the authors' knowledge, this is the first prospective, randomized, placebo-controlled trial of an antihypertensive medication conducted in US Hispanics only. Hispanics are the largest and fastest growing minority in the USA, with low rates of hypertension awareness and treatment and lower overall control rates [Lloyd-Jones et al. 2010; Ostchega et al. 2008 ]; yet, there is a paucity of prospectively designed hypertension trials that included significant proportions of Hispanics.
Most treatment-related data on Hispanics with hypertension have been collected from retrospective subgroup analyses from two randomized, active-controlled trials (ALLHAT [n ¼ 24,335; 16% Hispanics] [Lasagna, 2000] and INVEST [n ¼ 22, 576; 35. 6% Hispanics]) [Pepine et al. 2003] . From these two studies, only the ALLHAT prospectively defined change in BP as a primary endpoint. ALLHAT and INVEST data support the assertion that Hispanics are exposed to minority-selective risk factors for hypertension (e.g. obesity, diabetes, reduced access to care, and cultural barriers) [Flegal et al. 2010; Lloyd-Jones et al. 2010; Richardson and Norris, 2010; Chowdhury et al. 2006; Chobanian et al. 2003] , and suggest that the problem of poor BP control in the general Hispanic population is due to low Owing to a paucity of data on the use of betablockers in Hispanics, it is not possible to compare the results of our trial with results obtained using other beta-blockers; however, nebivolol should be well suited for the treatment of hypertension in a diabetes-, IGT-and obesity-burdened population such as Hispanics [Flegal et al. 2010; Manrique et al. 2009; Schmidt et al. 2007; Cossrow and Falkner, 2004; Poirier et al. 2001 ], due to its neutral effect on the metabolism of glucose and lipids [Fonseca, 2010] (unlike older-generation beta-blockers [Munzel and Gori, 2009] ), and NO-dependent vasodilatory properties [Munzel and Gori, 2009; Tzemos et al. 2001] .
The interpretation of this study is limited by several factors. First, the ethnic composition of participants in our trial (Cuban, 38%; Mexican, 26%) differed from the overall ethnic composition of Hispanics in the USA (Cuban, 6%; Mexican, 64%) (US Census Bureau, 2010).
Since there are differences in prevalence and incidence of CVDs and CVD-related mortality Figure 3 . Effect of nebivolol treatment on blood pressure in Hispanic participants with stage III hypertension by study visit (LOCF, ITT population). Mean change from baseline in DBP (A) and SBP (B) by week. *p < 0.05; **p < 0.01; ***p < 0.001; nebivolol versus placebo. DBP, diastolic blood pressure; ITT, intent-to-treat; LOCF, last observation carried forward; SBP, systolic blood pressure, SEM, standard error of the mean.
between Hispanic ethnicities, 3 the generalizability of our findings to the entire Hispanic population could be limited. Second, the effect of nebivolol in our study may be underestimated due to a relatively high placebo response, which may have resulted from participants' positive reaction to regular access to care (given that Hispanic ethnicity is associated with a lack of insurance and sources of regular care) [Stewart and Silverstein, 2002] , the subsequent familiarity of the participants with the study site personnel, or the relatively short duration (4 weeks) of the washout phase.
In summary, in Hispanics with stage III hypertension, nebivolol was significantly more effective than placebo in reducing blood pressure over an 8-week period, and was associated with significantly higher rates of blood pressure control. In addition, the safety and tolerability of nebivolol in Hispanics were similar to that of placebo. The results of this study provide direct evidence that the use of nebivolol may provide benefits in Hispanics with hypertension. 
